ArticleSultan Qaboos University medical journal2015
The Association between Human Leukocyte Antigens and Hypertensive End-Stage Renal Failure among Yemeni Patients.
Article in Sultan Qaboos University medical journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.
- Association between human leukocyte antigen (HLA) and end-stage renal disease (ESRD): a meta-analysis.PeerJ · 2023Pooled it
- Systematic review of associations between HLA and renal function.International journal of immunogenetics · 2022Pooled it
- Genetic susceptibility and HLA association in autoimmune hepatitis among Yemeni patients.BMC immunology · 2026Article
- Determination of HLA Tissue Type According to the Etiology of Patients with Chronic Renal Failure.Medeniyet medical journal · 2024Article
- Potential Involvement of Human Leukocyte Antigen-DR/DQ Polymorphisms with Schizophrenia Among Patients with Schizophrenia in Yemen.Oman medical journal · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMany studies have attempted to locate a connection between various genetic factors and the pathogenesis of certain diseases. A number of these have found human leukocyte antigens (HLAs) to be the most significant genetic factors affecting the susceptibility of an individual to a certain disease. The present case-control study aimed to determine the connection between class I and class II HLAs and cases of hypertensive end-stage renal failure (HESRF), as contrasted with healthy controls, in Yemen.
methodsThe study was carried out between March 2013 and March 2014 and included 50 HESRF patients attending the Urology & Nephrology Center at Al-Thawra University Hospital in Sana'a, Yemen, and 50 healthy controls visiting the same centre for kidney donation. Among both patients and controls, HLA class I (A, B and C) and class II (DRB1) genotypes were determined by polymerase chain reactions.
resultsThere was an association (odds ratio: 4.0) with HLA-A9(24) and HESRF, although this was not statistically significant. A significant protective function was found for the HLA-CW3 and DRB1-8 genes against the development of HESRF. Although HLA-B14 was present in some patients (0.06) and not in the controls, this difference was not statistically significant enough to conclude that HLA-B14 plays a role in the genetic predisposition for end-stage renal disease development. There was a high frequency of HLA-A2, B5, CW6, DRB1-3, DRB1-4 and DRB1-13 in both patients and controls.
conclusionAlthough no HLAs were found to play a highly significant role in genetic predisposition to HESRF, certain HLA genes could be considered as protective genes against HESRF development.
Indexed as
Identifiers
26052458PMC4450788W2425879408What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.